Keytone Ventures

MiRXES secures $77M Series C funding to accelerate multi-cancer early detection pipeline

Singapore-based biotechnology company MiRXES announced on Thursday it has raised $77 million in Series C funding to accelerate its push to deliver cancer early detection tests and…